Literature DB >> 24031658

Evaluation of biofilm production by Pseudomonas Aeruginosa isolates recovered from cystic fibrosis and non-cystic fibrosis patients.

L R R Perez1, M C N Costa, A L P Freitas, A L Barth.   

Abstract

Cystic fibrosis (CF) patients typically suffer of persistent and recurrent lung infections caused by Pseudomonas aeruginosa that many times possess ability for the biofilm production. Here, biofilm production among P. aeruginosa isolates recovered from sputum of CF and non-CF patients was evaluated. Most isolates were biofilm-producing independently of the patient's condition.

Entities:  

Keywords:  Pseudomonas aeruginosa; biofilm; cystic fibrosis

Year:  2011        PMID: 24031658      PMCID: PMC3769813          DOI: 10.1590/S1517-838220110002000011

Source DB:  PubMed          Journal:  Braz J Microbiol        ISSN: 1517-8382            Impact factor:   2.476


Cystic fibrosis (CF) is a genetic and chronic disease that affects the lower respiratory tract. This disease is characterized by excessive mucus production that covers the epithelium (2). Patients with CF present recurrent and persistent lung infections caused by Pseudomonas aeruginosa. In most of cases, the antimicrobial therapy is unable to eradicate the pseudomads infection. Despite also unclear, there is evidence that the biofilm formation is responsible, in part, for therapeutic failure (6, 7). Additionally, the biofilm mode of growth makes the bacteria more resistant to antimicrobial agents due to: 1) low penetration of the antimicrobial inside matrix; 2) alteration in the rate of bacterial growth; and 3) horizontal transference of elements genetically mobiles that possess genes of antimicrobial resistance (5, 8). Beside this, quorum sensing (QS) seems to be related to biofilm formation under certain growth conditions as such as medium of culture, temperature and atmosphere of incubation (4, 7). In the study presented here we evaluated the ability of biofilm formation among P. aeruginosa isolates recovered from cystic (CF+) and non-cystic fibrosis (CF-) patients. A total of 74 P. aeruginosa isolates recovered from sputum of patients hospitalized at Hospital de Clínicas de Porto Alegre (HCPA) were analyzed. All the isolates were identified by the use of WalkAway® 96SI system (Siemens), oxidase test and production of pigments. Of these, 35 and 39 isolates were recovered from CF+ and CF- patients, respectively. The age of the CF+ ranging from four to fifty-two years old. Among P. aeruginosa isolates from CF+, 30 isolates (85.7%) presented colony with mucoid aspect. Only five isolates recovered from younger patients did not present this mucoid phenotype. Patients without cystic fibrosis diagnosis did not present any chronical diseases but two patients that were admitted to intensive care unit were submitted to mechanical ventilation. Quantitative determination of biofilm was made using a microtitre plate assay in accordance with Stepanovic et al (10), with some modifications. Briefly, three to five colonies were suspended in 5 ml of Trypticase Soy Broth (TSB) and incubated during 18h at 35±1 °C, without shaking. After incubation, the stationary-phase culture was vortexed and thereafter diluted 1:100 in TSB with 0.25% glucose, and 200 μl of this solution was incubated in 96-well plates during 18h at 35±1 °C. Media with suspended bacteria was then removed; the plates were carefully washed four times with water and air-dried before staining with 200 μl of 0.9% crystal violet solution (Sigma, Stockholm, Sweden) for 15 min. After removing the dye solution and washing with water, the attached dye was solubilized with 95% ethanol and the optical density of the adherent biofilm was determined twice with a filter of 450/630nm in a microtitre plate reader (OrthoReader II, Ortho diagnostic systems, New Jersey, USA). In the experiments, we used TSB with 0.25% glucose as a negative control (background absorbance). All isolates were tested at least three times in triplicate. For interpretation of the biofilm results, the isolates were classified as follow: non-producing, weak, moderate and strong-producing, based on the following optic density (OD) average values: OD(isolate) ≤ OD(control) = non-biofilm-producing; OD(control) ≤ OD(isolate) ≤ 2OD(control) = weak-producing; 2OD(control) ≤ OD(isolate) ≤ 4OD(control) = moderate-producing; 4OD(control) ≤ OD(isolate) = strong-producing (10). Pseudomonas aeruginosa PAO1 (biofilm-producing) and P. aeruginosa ATCC 27853 (non-biofilm-producing) were used as controls. Biofilm production is often associated with microbial virulence and resistance (4). Although the mechanism is still poorly elucidated, some studies reported a great ability for biofilm production among P. aeruginosa isolates from CF+ mainly by their capacity of adaptation into cystic fibrosis lung (1, 3, 9). Similarly to other studies, we noted that most of the isolates from CF+ were able to produce biofilm “in vitro”. On the other hand, a high proportion of biofilm-producing isolates among that recovered from CF- can indicate that this characteristic is an important virulence factor that can be attributed to P. aeruginosa isolates from sputa, independently of the physiologic condition of the patient since we did not observe a statistically significant association between the presence of cystic fibrosis and biofilm production (p=0.6205). The OD450/630 values obtained to classify the isolates as non-producing, weak and moderate-biofilm-producing were OD450/630 ≤ 0,071; 0,071 < OD450/630 ≤ 0,142 and 0,142 < OD450/630 ≤ 0,284; respectively (Figure 1), considering a standard deviation value of 0.0034. A total of 74 isolates were analyzed and among all of them, the biofilm production was observed in 68% (50/74) of the isolates being the most classified as weak-producing (Table 1). Only two isolates, both from CF+, showed OD450/630 values of 0.156 (strain 34) and 0.1986 (strain 35) and were classified as moderate-biofilm-producing (Table 1 and Figure 1).
Figure 1

Biofilm production by Pseudomonas aeruginosa isolates. Black square represents CF+ and empty square represents CF-patients. Isolates yielding OD450/630 ≤ 0,071; 0,071 < OD450/630 ≤ 0,142 and 0,142 < OD450/630 ≤ 0,284 were considered to be non-producing, weak and moderate-biofilm-producing, respectively.

Table 1

Status of biofilm production among Pseudomonas aeruginosa isolates recovered from CF+ and CF- patients.

Cystic fibrosis (n° of isolates)Biofilm status
non-producingweakmoderatestrong
Yes (35)10232-
No (39)1425--
Biofilm production by Pseudomonas aeruginosa isolates. Black square represents CF+ and empty square represents CF-patients. Isolates yielding OD450/630 ≤ 0,071; 0,071 < OD450/630 ≤ 0,142 and 0,142 < OD450/630 ≤ 0,284 were considered to be non-producing, weak and moderate-biofilm-producing, respectively. Status of biofilm production among Pseudomonas aeruginosa isolates recovered from CF+ and CF- patients. Among isolates from CF+, 71.4% (25/35) were biofilm-producing while among isolates from CF-, 64.1% (25/39) were biofilm-producing. An important aspect of this study was that we used the microtiter assay as standard technique for evaluating of biofilm production. It is known that exist many techniques (electronic and confocal microscopy, Calgary device, flow continuous cell and others) that can be used for this aim and, for this reason, the interpretation of the results obtained from different methodologies can suffer some alterations (weak to moderate or moderate to strong, for example) (5, 10). In conclusion, our study demonstrated that most of P. aeruginosa isolates from cystic fibrosis have capacity to produce biofilm “in vitro”. Despite of this, most of them were classified as weak biofilm-producing by the methodology applied (microtiter assay). Although the cystic fibrosis isolates possess ability and flexibility to produce biofilm our results showed a high capacity of biofilm production “in vitro” among non-cystic fibrosis isolates as well. Further investigations including a higher number of isolates can be useful to elucidate the correlation between biofilm production and clinical condition of the patient.
  10 in total

Review 1.  [Activity of antimicrobial agents on bacterial biofilms].

Authors:  José Manuel Rodríguez-Martínez; Alvaro Pascual
Journal:  Enferm Infecc Microbiol Clin       Date:  2008-02       Impact factor: 1.731

2.  Quantification of biofilm in microtiter plates: overview of testing conditions and practical recommendations for assessment of biofilm production by staphylococci.

Authors:  Srdjan Stepanović; Dragana Vuković; Veronika Hola; Giovanni Di Bonaventura; Slobodanka Djukić; Ivana Cirković; Filip Ruzicka
Journal:  APMIS       Date:  2007-08       Impact factor: 3.205

Review 3.  Evolving concepts in biofilm infections.

Authors:  Luanne Hall-Stoodley; Paul Stoodley
Journal:  Cell Microbiol       Date:  2009-04-06       Impact factor: 3.715

4.  Quorum-sensing signals indicate that cystic fibrosis lungs are infected with bacterial biofilms.

Authors:  P K Singh; A L Schaefer; M R Parsek; T O Moninger; M J Welsh; E P Greenberg
Journal:  Nature       Date:  2000-10-12       Impact factor: 49.962

Review 5.  Biofilms: survival mechanisms of clinically relevant microorganisms.

Authors:  Rodney M Donlan; J William Costerton
Journal:  Clin Microbiol Rev       Date:  2002-04       Impact factor: 26.132

Review 6.  Pseudomonas aeruginosa biofilm formation in the cystic fibrosis airway.

Authors:  Sophie Moreau-Marquis; Bruce A Stanton; George A O'Toole
Journal:  Pulm Pharmacol Ther       Date:  2008-01-29       Impact factor: 3.410

Review 7.  Bugs, biofilms, and resistance in cystic fibrosis.

Authors:  Jane C Davies; Diana Bilton
Journal:  Respir Care       Date:  2009-05       Impact factor: 2.258

8.  Biofilm differentiation and dispersal in mucoid Pseudomonas aeruginosa isolates from patients with cystic fibrosis.

Authors:  Sylvia M Kirov; Jeremy S Webb; Che Y O'May; David W Reid; Jerry K K Woo; Scott A Rice; Staffan Kjelleberg
Journal:  Microbiology       Date:  2007-10       Impact factor: 2.777

Review 9.  Opportunistic infections in lung disease: Pseudomonas infections in cystic fibrosis.

Authors:  Marisa I Gómez; Alice Prince
Journal:  Curr Opin Pharmacol       Date:  2007-04-05       Impact factor: 5.547

10.  Interrelationships between colonies, biofilms, and planktonic cells of Pseudomonas aeruginosa.

Authors:  H Mikkelsen; Z Duck; K S Lilley; M Welch
Journal:  J Bacteriol       Date:  2007-01-12       Impact factor: 3.490

  10 in total
  10 in total

1.  Synergistic effects of pomegranate and rosemary extracts in combination with antibiotics against antibiotic resistance and biofilm formation of Pseudomonas aeruginosa.

Authors:  Wael Mohamed Abu El-Wafa; Rahma Hassanein Ahmed; Mohamed Abdel-Halim Ramadan
Journal:  Braz J Microbiol       Date:  2020-05-12       Impact factor: 2.476

2.  Biofilm Formation and β-Lactamase Production in Burn Isolates of Pseudomonas aeruginosa.

Authors:  Samira Heydari; Fereshteh Eftekhar
Journal:  Jundishapur J Microbiol       Date:  2015-03-21       Impact factor: 0.747

3.  Analysis of biofilm production by clinical isolates of Pseudomonas aeruginosa from patients with ventilator-associated pneumonia.

Authors:  Jailton Lobo da Costa Lima; Lilian Rodrigues Alves; Jussyêgles Niedja Pereira da Paz; Marcelle Aquino Rabelo; Maria Amélia Vieira Maciel; Marcia Maria Camargo de Morais
Journal:  Rev Bras Ter Intensiva       Date:  2017-09-04

4.  Molecular analysis and antimicrobial resistance pattern of distinct strains of Pseudomonas aeruginosa isolated from cystic fibrosis patients in Iran.

Authors:  Mohammad Emaneini; Davood Kalantar-Neyestanaki; Leila Jabalameli; Mojtaba Hashemi; Reza Beigverdi; Fereshteh Jabalameli
Journal:  Iran J Microbiol       Date:  2019-04

5.  A phenotypic and molecular investigation of biofilm formation in clinical samples of Pseudomonas aeruginosa.

Authors:  Leila Dolatshah; Mohammad Tabatabaei
Journal:  Mol Biol Res Commun       Date:  2021-12

6.  No Correlation between Biofilm-Forming Capacity and Antibiotic Resistance in Environmental Staphylococcus spp.: In Vitro Results.

Authors:  Matthew Gavino Donadu; Marco Ferrari; Vittorio Mazzarello; Stefania Zanetti; Ivan Kushkevych; Simon K-M R Rittmann; Anette Stájer; Zoltán Baráth; Dóra Szabó; Edit Urbán; Márió Gajdács
Journal:  Pathogens       Date:  2022-04-14

7.  Oxygen limitation favors the production of protein with antimicrobial activity in Pseudoalteromonas sp.

Authors:  Ruth López; Víctor Monteón; Ernesto Chan; Rubí Montejo; Manuel Chan
Journal:  Braz J Microbiol       Date:  2012-06-01       Impact factor: 2.476

8.  Evaluation of Different Phenotypic Techniques for the Detection of Slime Produced by Bacteria Isolated from Clinical Specimens.

Authors:  Rajkumar Hrv; Ramakrishna Devaki; Venkataramana Kandi
Journal:  Cureus       Date:  2016-02-23

9.  Effects of Lysozyme, Proteinase K, and Cephalosporins on Biofilm Formation by Clinical Isolates of Pseudomonas aeruginosa.

Authors:  Mohamed Eladawy; Mohammed El-Mowafy; Mohamed Mohamed Adel El-Sokkary; Rasha Barwa
Journal:  Interdiscip Perspect Infect Dis       Date:  2020-02-08

10.  Biofilm production by clinical isolates of Pseudomonas aeruginosa and structural changes in LasR protein of isolates non biofilm-producing.

Authors:  Jailton Lobo da Costa Lima; Lilian Rodrigues Alves; Paula Regina Luna de Araújo Jacomé; João Pacífico Bezerra Neto; Maria Amélia Vieira Maciel; Marcia Maria Camargo de Morais
Journal:  Braz J Infect Dis       Date:  2018-03-28       Impact factor: 3.257

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.